Our Work

We are inspired by companies, researchers and entrepreneurs who want to make a true difference We work with great clients and great people. Catalyze supports a variety of Life Sciences developments including, but not limited to, diagnostics, pharmaceuticals, medical devices and healthcare solutions. Our clients range from researchers at academic hospitals and universities, to non-profit organizations, start-ups,… Continue Reading

Imaging agent to determine colorectal cancer relapse

Imaging agent to determine colorectal cancer relapse

META-DETECT will develop a multi-target imaging agent to diagnose, stage and determine the risk of relapse in colorectal cancer (CRC).

Novel therapeutic antibody

Novel therapeutic antibody

NOVA-CARE aims to establish preclinical efficacy in mouse and porcine disease models for a novel therapeutic monoclonal antibody (mAb) to prevent non-ischaemic heart failure (NI-HF) by targeting EDA-fibronectin (EDA).

Highest Rated Eurostars Project

Highest Rated Eurostars Project

Dutch start-up Nutrileads and 4 partners from the Netherlands, Germany and Finland were awarded a € 2 million Eurostars project called NIMF. The NIMF project was the highest rated project with a Dutch participant, ranking 4th of 269 applications across all fields in Europe.

Next-generation allergy vaccine

Next-generation allergy vaccine

The TARGIT project will develop a next-generation allergy vaccine to treat grass-pollen induced allergic rhinitis and asthma effectively and life-long. The vaccine is based on unique glycans, covalently linked to clinically relevant grass pollen derived peptides.

Innovative organ-on-chip project

Innovative organ-on-chip project

The BONAFIDE project is an innovative organ-on-chip project. The consortium consists of ACTA (Academic Center for Dentistry Amsterdam) and industrial partners OcellO B.V. (Netherlands) and BEOnChip (Spain).

Novel therapeutic strategy to treat leukemia

Novel therapeutic strategy to treat leukemia

The ABC2ALL consortium will develop a novel therapeutic strategy to treat B-cell chronic lymphocytic leukemia (CLL).

Horizon2020 grant for innovative Rheumatoid Arthritis grant

Horizon2020 grant for innovative Rheumatoid Arthritis grant

The aim of the RABIOPRED project is to take the final steps in order to bring an innovative set of biomarkers that is able to predict response to treatment with TNF-α inhibitors in Rheumatoid Arthritis* (RA) to the market and clinical practice. The project was awarded a Horizon2020 grant.

Innovative diagnosis test for Alzheimer’s disease

Innovative diagnosis test for Alzheimer’s disease

There is an urgent medical need for a diagnostic tool for Alzheimer’s disease (AD) that is reliable, fast and non-invasive. Firalis SAS hold(s) an exclusive license on an innovative technology for an AD diagnosis test, based on the detection of two complementary biomarkers in red blood cells.